Espicom publishes over 135 reports on companies developing anti-cancer drugs from the largest blue-chip multinational to smaller specialist organisations - and all phases of development from research to launched products.

For each company you can evaluate:
* Summary: At a glance review of agreements, products and R&D pipeline.
* Overview: Background, ownership structure and research techniques they have developed for drug discovery.
* Agreements: Key details of who the company is collaborating with, and on what.
* Product Portfolio: Product monographs, mechanism of action and indications approved and in development.
* R&D Pipeline: Concise summaries of products in research covering status, indication and clinical trials.
* Financials: An analysis of financial performance including P&L, R&D expenditure and funding. Cell Therapeutics Inc (CTI) was incorporated in Washington in September 1991 and commenced operations in
February 1992. The company focuses on the discovery, development and commercialisation of drugs for the treatment
of cancer. CTI's goal is to build a leading, vertically-integrated biopharmaceutical company with a diversified portfolio of
proprietary oncology drugs. Its research and in-licensing activities are concentrated on identifying new, less toxic and
more effective ways to treat cancer.